Core Insights - SENO showcased its oral thin film technology at the International Vaping Exhibition in Paris, highlighting its commitment to meet evolving regulatory expectations and consumer preferences in Europe [1][5][7] Group 1: Product Innovation and Market Demand - SENO's oral thin film technology is designed for portability, discreet use, and controlled dosing, aligning with the increasing demand for compliant nicotine delivery alternatives in Europe [3][8] - The company has invested in compliance systems and refined its product framework to meet regional standards, establishing a structured presence across multiple European markets [4][8] Group 2: Strategic Engagement and Industry Recognition - The Paris exhibition marked a significant milestone for SENO, with strong engagement from distributors and buyers from key markets such as France, Germany, and Italy, indicating a growing interest in alternative nicotine technologies [5][6] - Industry participants recognized oral thin film delivery systems as a viable addition to the smoke-free category, reinforcing SENO's positioning within this emerging segment [7][10] Group 3: Expansion into New Categories - SENO announced the debut of its CBD Concept Oral Thin Film, marking its entry into the functional film category and reflecting a strategic diversification beyond nicotine delivery systems [12][14] - The CBD concept product aims to explore use cases related to relaxation and stress management, utilizing SENO's proprietary carrier system for controlled cannabinoid delivery [13][14] Group 4: Future Growth Strategy - SENO emphasizes research and development as central to its growth strategy, with ongoing investments in formulation science and delivery technologies to support expansion into new markets and product categories [15][16] - The company aims to streamline product development and market entry processes globally while ensuring compliance across diverse regulatory environments [16][17]